These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12448673)

  • 1. Respiratory infections.
    Cant AJ; Gordon SB; Read RC; Hart CA; Winstanley C
    J Med Microbiol; 2002 Nov; 51(11):903-914. PubMed ID: 12448673
    [No Abstract]   [Full Text] [Related]  

  • 2. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
    Lee WK; Young BW
    J Antimicrob Chemother; 2005 Sep; 56(3):603-5. PubMed ID: 16040621
    [No Abstract]   [Full Text] [Related]  

  • 4. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections.
    Bishai W
    Clin Ther; 2002 Jun; 24(6):838-50; discussion 837. PubMed ID: 12117077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany].
    Höffken G; Lorenz J; Kern W; Welte T; Bauer T; Dalhoff K; Dietrich E; Ewig S; Gastmeier P; Grabein B; Halle E; Kolditz M; Marre R; Sitter H; ; ;
    Pneumologie; 2009 Oct; 63(10):e1-68. PubMed ID: 19821215
    [No Abstract]   [Full Text] [Related]  

  • 6. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of fluoroquinolones in respiratory tract infections: community acquired pneumonia.
    García-Rodríguez JA; Muñoz Bellido JL
    Int J Antimicrob Agents; 2000 Nov; 16(3):281-5. PubMed ID: 11091048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical assessment of tosufloxacin tosilate.
    Kohno S
    J Infect Chemother; 2002 Mar; 8(1):19-27. PubMed ID: 11957115
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibiotic resistance of S. pneumoniae and H. influenzae strains isolated from patients with community acquired respiratory tract infections. BACTRO multicenter, multidisciplinary study].
    Tudose C; Bumbăcea D; Bogdan M;
    Pneumologia; 2011; 60(1):30-5. PubMed ID: 21548198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin and lower respiratory tract infections.
    Blasi F; Cazzola M; Tarsia P; Cosentini R; Aliberti S; Santus P; Allegra L
    Expert Opin Pharmacother; 2005 Oct; 6(13):2335-51. PubMed ID: 16218893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
    Govan JR; Brown AR; Jones AM
    Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
    Ball P
    Int J Antimicrob Agents; 2000 Nov; 16(3):263-72. PubMed ID: 11091046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemifloxacin: survival of the fittest.
    Mandell L
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiology of cystic fibrosis lung infections: themes and issues.
    Govan JR; Nelson JW
    J R Soc Med; 1993; 86 Suppl 20(Suppl 20):11-8. PubMed ID: 7684788
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pneumonia in the antibiotic era].
    He L
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 Apr; 22(4):197-8. PubMed ID: 11775912
    [No Abstract]   [Full Text] [Related]  

  • 18. An update on community-acquired pneumonia in adults.
    Gotfried M; Freeman C
    Compr Ther; 2000; 26(4):283-93. PubMed ID: 11126100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penicillin resistance in pneumococcal pneumonia. Antibiotics with low resistance potential are effective and pose less risk.
    Cunha BA
    Postgrad Med; 2003 Jan; 113(1):42-4, 47-8, 52-4. PubMed ID: 12545592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae.
    Moellering RC; Craig W; Edmond M; Farrell DJ; Ferraro MJ; File TM; Klein J; Lonks J; Metlay JP; Sahm D; Talbot GH;
    J Chemother; 2002 Jul; 14 Suppl 3():42-56. PubMed ID: 12418560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.